Telix Pharmaceuticals (ASX:TLX) has delivered robust revenue growth alongside meaningful progress across its therapeutics pipeline in the three months to the end of March 2026.
Revenue for the quarter reached US$230 million, reflecting a notable rise from both the previous quarter and the same period last year, while reinforcing full-year guidance that approaches the billion-dollar mark.
This growth has been driven primarily by the Precision Medicine segment, where imaging products are gaining traction in global markets. The growing adoption of these products, particularly in the United States, indicates deeper clinical adoption as physicians integrate these diagnostics more routinely into patient care pathways.
The company said its dual-product strategy in PSMA imaging is beginning to translate into measurable market share gains, supported by a distribution model that has proven resilient even under operational stress such as severe weather conditions in North America.
The company’s lead prostate cancer therapy candidate has successfully met early safety and dosimetry objectives in its Phase 3 trial, an important milestone that de-risks subsequent stages of development. At the same time, the absence of adverse drug interactions in combination with existing standards of care strengthens its potential positioning within treatment protocols, an essential consideration for eventual market adoption.
Trials targeting kidney cancer, glioblastoma, and bone metastases are progressing across multiple geographies, reflecting a strategy that balances diversification with focus on high unmet medical needs. Early data from next-generation candidates also suggest improvements in biodistribution, pointing toward therapies that may offer enhanced efficacy with reduced off-target effects.
The resubmission of a New Drug Application for a brain cancer imaging agent in the United States, alongside a European filing for the same candidate, indicates progress in the underlying clinical data and a commitment to expanding access across major markets.
Managing Director and Group CEO, Dr Christian Behrenbruch, said, “Growth accelerated across our Precision Medicine business in the first quarter, with US dose volumes increasing 5% quarterover-quarter. This performance reflects the growing uptake of Gozellix alongside Illuccix, contributing to market share gains underpinned by disciplined sales execution and pricing, and high-quality service delivery despite extreme North American weather conditions, an advantage of the pharmacy distribution model. With our two-product PSMA9 imaging strategy, differentiated clinical positioning and expanding commercial presence globally, we are seeing a solid foundation for continued growth through 2026. Importantly, we are delivering on our strategic priorities to advance our high-value clinical programs, demonstrated by the momentum in our therapeutics pipeline this quarter."